SCHEMBL28359074

SCHEMBL28359074

O=C(C#Cc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VCP P55072 1/20 0.59
▸ HSP90AA1 P07900 5/20 0.53
▸ MAPT P10636 4/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ NPSR1 Q6W5P4 3/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ OPRK1 P41145 2/20 0.53
▸ CES2 O00748 1/20 0.52
▸ CES1 P23141 1/20 0.52
▸ NTSR1 P30989 1/20 0.50
▸ HTT P42858 2/20 0.49
▸ S1PR2 O95136 1/20 0.49
▸ MITF O75030 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ APP P05067 4/20 0.49
▸ MAOB P27338 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ AGTR1 P30556 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8652597 0.93 VCP (0.69) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL28745823 0.89 APP (0.56) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL978641 0.86 VCP (0.75) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL13077510 0.83 APP (0.69) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL28972921 0.82 GPR183 (0.51) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL10625119 0.82 VCP (0.81) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL28542054 0.81 VCP (0.59) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL16582689 0.81 VCP (0.86) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL10070193 0.81 VCP (0.58) VCPHSP90AA1MAPTALDH1A1KMT2A
SCHEMBL30055393 0.81 HSP90AA1 (0.60) VCPHSP90AA1MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-06-12 — — US disclosed
CN-116354914-B Triphenylsubstituted pyrone derivative and synthetic method and application thereof 河南科技大学 2024-09-03 — — CN disclosed
EP-4333819-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY Katholieke Universiteit Leuven (BE) 2024-03-13 — — EP disclosed
CN-116354914-A Triphenylsubstituted pyrone derivative and synthetic method and application thereof 河南科技大学 2023-06-30 — — CN disclosed
WO-2022233877-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-11-10 — — WO disclosed
CN-110627626-B Preparation method of propargyl acetone compound 内蒙古大学 2022-04-26 — — CN disclosed
CN-108148064-B Method for preparing pyrazole quinoxalinone derivative 浙江百斯特化工有限公司 2020-06-26 — — CN disclosed
CN-110627626-A Preparation method of propargyl acetone compound 内蒙古大学 2019-12-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY CNR1, CNR2, CYP2J2 VCP 4323/4885HSP90AA1 3775/4885MAPT 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback